Why Ocugen Stock Rallied Today
Shares of Ocugen (NASDAQ: OCGN) rose on Tuesday after the biotechnology company struck a deal with Jubilant HollisterStier to manufacture Covaxin in the U.S. By the close of trading, Ocugen's stock price was up 2% after rising as much as 19.9% earlier in the day.
The agreement comes after Ocugen's announcement on Thursday that it would forego the pursuit of an emergency use authorization (EUA) for Covaxin from the U.S. Food and Drug Administration. Instead, Ocugen will strive to obtain a biologics license application, a process that's likely to take a significantly greater amount of time.
"We are fully committed to bringing Covaxin to the U.S. and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants," Ocugen Senior Vice President J.P. Gabriel said in a press release. "Securing U.S.-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada."
Source Fool.com
